About Longeveron Inc. - Class A Common stock (LGVN)
Longeveron Inc is a biotechnology company focused on developing cellular therapies to address age-related and life-threatening conditions. The company specializes in the research and commercialization of innovative treatments, particularly those utilizing mesenchymal stem cells derived from umbilical cord tissue. Longeveron aims to improve the quality of life for patients suffering from diseases such as Alzheimer’s and cardiac dysfunction by harnessing the potential of these advanced therapies to promote regeneration and improve overall health outcomes. Through its commitment to scientific research and clinical trials, Longeveron is at the forefront of modern medicine, exploring new avenues for healing and enhancing longevity. Read More
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met
Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.
Longeveron Inc. (LGVN) reported Q2 2025 earnings with revenue missing estimates at $320K but a narrower EPS loss of $0.33. Stock fell 3.5% post-earnings amid clinical progress in HLHS and Alzheimer's trials.
